Maven Securities LTD Takes $4.02 Million Position in Protara Therapeutics, Inc. $TARA

Maven Securities LTD purchased a new stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 754,626 shares of the company’s stock, valued at approximately $4,022,000.

A number of other large investors have also recently modified their holdings of the business. Barclays PLC boosted its position in shares of Protara Therapeutics by 21.0% during the 4th quarter. Barclays PLC now owns 55,057 shares of the company’s stock valued at $293,000 after acquiring an additional 9,537 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Protara Therapeutics by 104.7% during the 4th quarter. Marshall Wace LLP now owns 584,528 shares of the company’s stock worth $3,116,000 after acquiring an additional 298,942 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in Protara Therapeutics in the fourth quarter worth $59,000. Walleye Capital LLC purchased a new position in Protara Therapeutics in the fourth quarter worth $778,000. Finally, Alyeska Investment Group L.P. purchased a new position in Protara Therapeutics in the fourth quarter worth $1,866,000. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Stock Performance

Shares of TARA stock opened at $3.90 on Monday. Protara Therapeutics, Inc. has a fifty-two week low of $2.77 and a fifty-two week high of $7.82. The stock has a 50 day moving average price of $4.90 and a two-hundred day moving average price of $5.56. The company has a market capitalization of $219.18 million, a P/E ratio of -2.91 and a beta of 1.45.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.05. As a group, equities analysts predict that Protara Therapeutics, Inc. will post -1.45 earnings per share for the current year.

Insider Activity

In other news, insider Jacqueline Zummo sold 22,598 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total transaction of $118,865.48. Following the transaction, the insider directly owned 95,961 shares of the company’s stock, valued at approximately $504,754.86. The trade was a 19.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 7.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Oppenheimer boosted their target price on Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Tuesday, April 21st. TD Cowen restated a “buy” rating on shares of Protara Therapeutics in a research report on Tuesday, March 10th. Finally, Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Protara Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $26.25.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.